- Funding to support the advancement of company’s novel oral p300/CBP inhibitor, inobrodib for the treatment of multiple myeloma
- In 2024, CellCentric released promising efficacy & safety data at the American Society of Hematology (ASH) Annual Meeting.
Cambridge, UK and Boston, MA – May 19, 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round. The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm. The funding will further support the advancement of CellCentric’s novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma.
A phase IIa dose optimisation clinical study is ongoing with an all-oral triplet of inobrodib combined with pomalidomide and dexamethasone. Proceeds from the Series C financing will be used to support:
- Initiation of a Phase II/III study in heavily pretreated multiple myeloma patients, with the potential to support an accelerated approval.
- Support development activities for a Phase III program, to start mid-2026.
- Initiation of trials starting Q2 2025, including the combination of inobrodib with bi-specific antibodies, as well as inobrodib in a maintenance setting.
Despite significant recent progress in treating multiple myeloma, the majority of patients still succumb to the disease. A large number of patients are not eligible for, or become resistant to, the latest therapies. Inobrodib’s truly novel mechanism of action, oral delivery, and favorable safety profile make it an attractive additional option. It has the potential to become an agent used across multiple settings, with different combination agents.
Will West, CEO of CellCentric, stated: ”We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today’s announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team.”
Jasper Bos, General Partner at Forbion, who is joining the CellCentric Board, added: “CellCentric has developed an innovative and impactful therapy for multiple myeloma with inobrodib, a first-in-class oral p300/CBP inhibitor. This novel agent has demonstrated promising efficacy and a manageable safety profile in early clinical trials. We are enthusiastic about supporting CellCentric as it advances inobrodib into registration studies, aiming to transform multiple myeloma treatment across various stages of the disease.”
In 2023, the FDA granted Fast Track and orphan drug designation to inobrodib for treating relapsed or refractory multiple myeloma. Last year, CellCentric released promising efficacy and safety data at the American Society of Hematology (ASH) Annual Meeting. The company has achieved several significant milestones, including an initial $35 million investment from RA Capital last year as well as a $25 million strategic investment from Pfizer. This month, a new CellCentric office opened in Burlington MA, just outside Boston, as the company builds its team globally.
About inobrodib
Inobrodib is a new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, MYC and IRF4. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. As it has a good safety profile for a drug in this setting, it may be used by those who are unable to access or tolerate other types of treatment. It has the potential to present a lower overall burden on the healthcare system as compared to more complex agents.
About CellCentric
CellCentric is an innovative biotechnology company with offices in the UK and US. The company was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of targeting cell fate control mechanisms.
About Forbion
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion’s team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 128 investments across 11 funds. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
About RA Capital Management, LP RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization.
